NCT03790865: A reported trial by Millendo Therapeutics SAS
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03790865 |
|---|---|
| Title | A Phase 2b/3 Study to Evaluate the Safety, Tolerability, and Effects of Livoletide (AZP-531), an Unacylated Ghrelin Analogue, on Food-related Behaviors in Patients With Prader-Willi Syndrome |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 25, 2019 |
| Completion date | Feb. 26, 2020 |
| Required reporting date | Feb. 25, 2021, midnight |
| Actual reporting date | Jan. 21, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |